Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.08, Zacks reports.
Relmada Therapeutics Price Performance
Shares of Relmada Therapeutics stock opened at $0.30 on Friday. Relmada Therapeutics has a 1-year low of $0.24 and a 1-year high of $5.09. The company has a market capitalization of $8.95 million, a P/E ratio of -0.10 and a beta of 0.65. The business’s fifty day moving average price is $0.31 and its two-hundred day moving average price is $1.60.
Analyst Ratings Changes
RLMD has been the subject of a number of research reports. Mizuho restated a “neutral” rating and issued a $1.00 target price (down from $23.00) on shares of Relmada Therapeutics in a research note on Thursday, December 5th. Leerink Partners reissued a “market perform” rating and set a $1.00 price target (down previously from $10.00) on shares of Relmada Therapeutics in a report on Wednesday, December 4th. Finally, Leerink Partnrs lowered shares of Relmada Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.25.
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
See Also
- Five stocks we like better than Relmada Therapeutics
- Insider Buying Explained: What Investors Need to Know
- MarketBeat Week in Review – 03/24 – 03/28
- There Are Different Types of Stock To Invest In
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Roth IRA Calculator: Calculate Your Potential Returns
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
